A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 4	2026-09-25		NCT07030517

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Johnson & Johnson Private Limited	2

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
All India Institute of Medical Sciences	New Delhi	India	26
Bhagwan Mahaveer Cancer Hospital & Research Centre	Jaipur	India	4
Christian Medical College	Ratnagiri Kilminnal	India	1
Jawaharlal Institute Of Postgraduate Medical Education And Research	Puducherry	India	3
KIMS-Kingsway Hospitals	Nagpur	India	2
M S Ramaiah Medical College and Hospital	Bangalore	India	2
Post Graduate Institute of Medical Education And Research PGIMER	Chandigarh	India	3
Rajiv Gandhi Cancer Institute & Research Centre	New Delhi	India	3
Regional Cancer Centre	Thiruvananthapuram	India	1
St. Johns Medical College And Hospital	Bengaluru	India	1
Tata Medical Center	Kolkata	India	2
Tata Memorial Hospital	Mumbai	India	11